What is the biologic of choice in a patient with RA and history of non-melanoma skin cancer?

We have long known that patients treated with TNF inhibitors (TNFi) have a higher risk of developing non-melanoma skin cancers. For this reason, all patients prescribed these drugs should undergo annual full-body dermatology skin exams. If this recommendation is followed, there should be no contrain...

The literature has demonstrated an increased risk of varying degrees of nonmelanoma skin cancer with all biologics. Comparative studies are difficult to interpret as most RA patients have received other biologic therapies prior to the use of nonTNFi biologics or methotrexate, which itself has been a...